Health Condition 1: N71- Inflammatory disease of uterus, except cervix
Conditions
Interventions
Intervention1: Benfotiamine tablets and
Limcee tablets: T Benfotiamine 100MG, Per oral, Once a day, 3 months
T Limcee 500MG, Per oral,Twice a day,3 months
Control Intervention1: PLACEBO: EXCIPIENTS,
Sponsors
Kaviya V
Eligibility
Inclusion criteria
Inclusion criteria: Single / not in a relationship Primary dysmenorrhoea moderate to severe in most of the cycles for minimum 6 months. No underlying gynaecology problem . Not on any drug intake. Should not take any other medication for dysmenorrhoea
Exclusion criteria
Exclusion criteria: Age less than 15 or more than 30 Secondary dysmenorrhoea or any other underlying gynaecology problem. Any abdominal / pelvic surgery . Smoking , drinking , taking hormonal drugs and ocps and severe mental tensions during research . Any kind of physical / mental disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on intensity and duration of pain by using VAS Effect on quality of life- QOL using WALIDD Score. Effect on vasoconstriction in uterine muscles by PI and RI of uterine vasculature.Timepoint: Pre- intervention 3 months post intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect on markers for primary dysmenorrhoea [ hsCRP,PGE2 ,PGF2alpha and ADMA). Drug complications, Amount of patient satisfactionTimepoint: pre - intervention 3 months post intervention | — |
Countries
India
Contacts
Public ContactDr. V Kaviya
SRM Insitute of Science and Technology
Outcome results
None listed